Grey Wolf Therapeutics names new non-director to Australian subsidiary's board.

M2 EQUITYBITES-July 29, 2022-Grey Wolf Therapeutics names new non-director to Australian subsidiary's board

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Grey Wolf Therapeutics, a UK-based biotechnology company, announced on Thursday that it has named Brett Carter as a non-executive director to the board of its Australian subsidiary.

Carter has over 20 years of global biopharmaceutical industry experience. He has served as chief executive officer of Australia's Cancer Therapeutics Cooperative Research Centre (now Canthera Discovery). He has served as a strategic advisor to several biotechnology...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT